| abstract |
The present invention relates to (a) alpha-isoform-specific phosphatidylinositol-3-kinase inhibitor (S) -pyrrolidine-1,2-dicarboxylic acid 2- Amide 1 - ({4-Methyl-5- [2- (2,2,2-trifluoro-1,1-dimethyl-ethyl) -pyridin-4-yl] -thiazol- ), Or any pharmaceutically acceptable salt thereof; (b) an mTOR inhibitor; and (c) an exemestane or any pharmaceutically acceptable salt thereof; The use of such a combination in the manufacture of a medicament for the treatment or prevention of a proliferative disease; A pharmaceutical composition of a combination of the above therapeutic agents, and a method of treating a proliferative disease in the subject, comprising administering to the subject a therapeutically effective amount of such a combination. |